28 January 2020
Coulter Partners secures Chief Financial Officer for Stilla Technologies
Coulter Partners was delighted to partner recently with Stilla Technologies, provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, to secure the appointment of Khaled Bahi as Chief Financial Officer. His appointment comes at a time of rapid growth for the company, with the recent opening of a U.S. subsidiary headquartered in Beverly, Massachusetts, providing American customers with direct sales and support, including a demo lab and training center. Life science veteran Ruth Szebries — with more than 34 years of experience leading U.S. subsidiaries for foreign companies such as BGI and Exiqon — runs Stilla’s U.S. subsidiary as General Manager and Vice President of Commercial Operations for the Americas.
Since 2016, Stilla Technologies has been providing research organizations specialized in molecular biology and genetic analysis with its Naica™ System, a ground-breaking digital PCR (polymerase chain reaction) solution that enables scientists to detect and quantify DNA mutations with unrivalled precision.
“I am proud to welcome Khaled to the Stilla team at this important time in our company’s growth and thank the team at Coulter Partners for their outstanding professional support in achieving this quality appointment,” said Rémi Dangla, Ph.D., Stilla’s CEO, cofounder and inventor of the company’s technology. “The expansion of our team is both evidence of our success and key to our ability to continue to accelerate adoption of the Naica™ Crystal Digital PCR™ System as we bring next-generation digital PCR to the mainstream.”
Khaled Bahi, 53, joined Stilla Technologies in November 2019 as Chief Financial Officer. A German national, Khaled has more than 20 years of experience in the Medtech industry, where he has worked on both the financial and operational sides. Previously, Khaled was the CFO of the Swiss cardiovascular company Symetis, which was acquired by Boston Scientific in the middle of an IPO. Before that, he worked for 15 years at various positions for Fresenius Medical Care. Khaled holds a Master of Science degree in Physics from ETH Zurich.
About Stilla Technologies
Founded in 2013 at Ecole Polytechnique, Stilla Technologies is a Paris-based life sciences company focused on accelerating the development of next-generation genetic tests by providing a groundbreaking and flexible digital PCR solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla technologies aims to make dPCR a lab commodity for all areas of the life sciences. Stilla actively advises and supports its customers worldwide through its dynamic and multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.
For more information about Stilla Technologies, please visit www.stillatechnologies.com